293 related articles for article (PubMed ID: 37254917)
1. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
2. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
5. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to targeted protein degradation technologies in drug discovery.
Xue Y; Bolinger AA; Zhou J
Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
[TBL] [Abstract][Full Text] [Related]
7. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
8. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
Cassidy K; Zhao H
Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
[TBL] [Abstract][Full Text] [Related]
9. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation in drug development: Recent advances and future challenges.
Song J; Hu M; Zhou J; Xie S; Li T; Li Y
Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
[TBL] [Abstract][Full Text] [Related]
11. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
12. Proteomic approaches advancing targeted protein degradation.
Sathe G; Sapkota GP
Trends Pharmacol Sci; 2023 Nov; 44(11):786-801. PubMed ID: 37778939
[TBL] [Abstract][Full Text] [Related]
13. Target and tissue selectivity of PROTAC degraders.
Guenette RG; Yang SW; Min J; Pei B; Potts PR
Chem Soc Rev; 2022 Jul; 51(14):5740-5756. PubMed ID: 35587208
[TBL] [Abstract][Full Text] [Related]
14. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs.
Alabi SB; Crews CM
J Biol Chem; 2021; 296():100647. PubMed ID: 33839157
[TBL] [Abstract][Full Text] [Related]
15. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
16. Clinical Translation of Targeted Protein Degraders.
Kong NR; Jones LH
Clin Pharmacol Ther; 2023 Sep; 114(3):558-568. PubMed ID: 37399310
[TBL] [Abstract][Full Text] [Related]
17. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-MartÃnez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
18. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).
Wang H; Zhou R; Xu F; Yang K; Zheng L; Zhao P; Shi G; Dai L; Xu C; Yu L; Li Z; Wang J; Wang J
Biomater Res; 2023 Jul; 27(1):72. PubMed ID: 37480049
[TBL] [Abstract][Full Text] [Related]
19. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
20. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
